BioCardia, Inc. BCDA
Set alert
0.86 USD -0.07 -7.02%
At close · Oct 30
0.86 0.00 0.00%
After hours · Oct 30, 5:45 PM ET
0.861 Day range 0.92
0.77 52-week range 1.47
- YTD
- -31.12%
- 1 year
- -31.67%
- Open
- 0.92
- Prev close
- 0.926
- Mkt cap
- 13.03M
- Vol
- 79.32K
- Avg vol
- 243.28K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.861
- High
- 0.92
- Forward P/E
- -1.57
- Beta
- 1.27
- Short ratio
- 1.41
- Inst. own
- 2.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.28
- 200-d avg
- 3.62
- 1y target
- 25.00
5Y chart
Events in this range
- Aug 9, 2023Earnings: -2.55; estimate -2.25; surprise -13.33%
- Nov 8, 2023Earnings: -1.8; estimate -1.8; surprise 0%
- Mar 27, 2024Earnings: -1.35; estimate -1.65; surprise 18.18%
- May 14, 2024Earnings: -1.35; estimate 0; surprise —%
- May 30, 2024Split: 1 for 14
- Jul 26, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 13, 2024Earnings: -0.88; estimate -0.1; surprise -780%
- Aug 16, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 21, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Oct 28, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 13, 2024Earnings: -0.61; estimate -1.19; surprise 48.74%
- Nov 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (95)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 1 day ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Jan 19, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 9 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 23, 2024 | 1 year ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| SMA: Bullish | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| SMA: Bearish | Aug 19, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| RSI: Oversold | Aug 5, 2024 | 2 years ago |
| RSI: Oversold | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 8, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 24, 2024 | 2 years ago |
| RSI: Oversold | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | May 6, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| MACD: Sell Signal | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | Jul 17, 2023 | 3 years ago |
| SMA: Bearish | Jul 17, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 24, 2023 | 3 years ago |
| SMA: Bearish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Mar 13, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 2, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Oct 24, 2022 | 4 years ago |
| SMA: Bullish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 8, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Jan 31, 2022 | 4 years ago |
Key statistics
- Market cap
- 9.17M
- Enterprise value
- 4.00M
- Trailing P/E
- 0.00
- Forward P/E
- -1.57
- PEG ratio
- 0.00
- Price / sales
- 21.42
- Price / book
- 0.00
- EPS (TTM)
- -4.03
- Beta
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 428.00K
- Revenue growth
- -93.00%
- Free cash flow
- -3.85M
- Total cash
- 1.42M
- Total debt
- 1.14M
- Return on equity
- 0.00%
- Shares outstanding
- 4.58M
- Short % of float
- 2.65%
- 50-day average
- 2.28
- 200-day average
- 3.62
Analyst view
Consensus: none
Price target (mean) 25.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.87.
Financials — quick view
BCDA Revenue — quarterly 0
BCDA Net income — quarterly -1.61M
BCDA EPS — quarterly -0.13
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.19 | -0.61 | +0.58 | +48.74% |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | -0.88 | -0.78 | -780.00% |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.35 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -1.65 | -1.35 | +0.30 | +18.18% |
| Nov 8, 2023 | Sep 1, 2023 | -1.80 | -1.80 | 0.00 | 0.00% |
| Aug 9, 2023 | Jun 1, 2023 | -2.25 | -2.55 | -0.30 | -13.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biocardia.com
News
- BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery
- BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
- BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
- BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart
- BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
- BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
- BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
- BioCardia Shares Fall 10% After Hours: Here's Why
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
Your note
Sign in to keep a note on BCDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN JIM L | Director | Stock Award(Grant) | Sep 2, 2024 | 109,673 |
| ALTMAN PETER | Chief Executive Officer | Purchase | Dec 4, 2024 | 105,581 |
| BLANK ANDREW SCOTT | Director | Stock Award(Grant) | Sep 2, 2024 | 0 |
| FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 18, 2024 | 0 |
| GILLIS EDWARD M | Officer | Stock Award(Grant) | May 17, 2023 | 40,490 |
| MCCLUNG DAVID | Chief Financial Officer | Stock Award(Grant) | Oct 10, 2024 | 30,008 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 1.54% | 70,596 | 141.19K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.32% | 14,736 | 29.47K | Sep 29, 2024 |
| Vanguard Group Inc | 0.28% | 12,884 | 25.77K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 1,282 | 2.56K | Sep 29, 2024 |
| Pingora Partners LLC | 0.02% | 1,036 | 2.07K | Sep 29, 2024 |
| Global Retirement Partners, LLC | 0.01% | 411 | 822 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.28% | 12,616 | 25.23K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 7,967 | 15.93K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 3,237 | 6.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 2,964 | 5.93K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 2,162 | 4.32K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 47 | 94 | Sep 29, 2024 |